This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
The LD<sub>50</sub> of MiPLA is unknown. Adverse psychological reactions are common especially at higher dosages. Some of these include [[anxiety]], [[delusions]], [[panic attacks]] and more rarely [[seizures]]. Medical attention is usually only needed if suspected of severe psychotic episodes or “fake acid” (such as [[25i-NBOMe]] or [[DOB]]). Administration of [[benzodiazepines]] or [[antipsychotics]] can help to relieve the negative cognitive effects of MiPLA.
The LD<sub>50</sub> of MiPLA is unknown. Adverse psychological reactions may be become more likely to occur at higher doses. Some of these include [[anxiety]], [[delusions]], [[panic attacks]] and more rarely [[seizures]]. Medical attention is usually only needed if suspected of severe psychotic episodes or “fake acid” (such as [[25i-NBOMe]] or [[DOB]]). Administration of [[benzodiazepines]] or [[antipsychotics]] can help to relieve the negative cognitive effects of MiPLA.
===Dangerous interactions===
===Dangerous interactions===
Revision as of 19:54, 24 October 2018
N-Methyl-N-isopropyllysergamide (also known as methylisopropyllysergamide, Lamide and MiPLA) is a novel psychedelic substance of the lysergamide class. MiPLA is chemically similar to LSD and has a similar mechanism of action, working primarily by stimulating serotoninreceptors in the brain.
MiPLA was first discovered by Albert Hoffman as a part of the original structure-activity research into LSD. It has recently been researched in greater detail by by the team led by David E. Nichols at Purdue University. MiPLA and its effects are also mentioned in Alexander Shulgin's Pharmacology notes #9 and Pharmacology notes C,
User reports describe the effects of MiPLA as similar to those of LSD with major differences. It is thought to be 1/3rd as potent as LSD itself, with an active dose reported at between 100-200 micrograms. It is often described as being more mentally and physically oriented but with a less introspective headspace and subtle, albeit pronounced visuals. It also has a notably shorter duration at 4-6 hours and is generally described as less anxiety-provoking than other lysergamides.
Very little data exists about the pharmacological properties, metabolism, and toxicity of MiPLA. While it is often characterized by users as being generally more recreational and non-threatening compared to LSD, it is highly advised to approach this highly potent hallucinogenic substance with the proper amount of precaution and harm reduction practices if using it.
The chemical name of MiPLA is methylisopropyllysergamide. MiPLA belongs to a class of organic compounds known as lysergamides, which are a subclass of ergolines (derivatives of the alkaloids found in the ergot fungus). The most prominent member of the lysergamides is LSD, lysergic acid diethylamide.
MiPLA is a structural isomer of LSD. Like LSD, the chemical structure of MiPLA is based on the lysergic acid amide structural skeleton. However, whereas LSD has two ethyl groups bound to the amide nitrogen, MiPLA is substituted with a methyl and isopropyl group.
MiPLA is a chiral compound with two stereocenters at R5 and R8. The differences in psychoactivity between the stereoisomers has not been investigated.
The physical properties of MiPLA have not been documented in the scientific literature.
Pharmacology
Subjective effects
MiPLA is commonly reported to be significantly shorter in its duration and less uncomfortable in both its negative physical side effects and general anxiety.
Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWikicontributors. As a result, they should be viewed with a healthy degree of skepticism.
It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.
Physical effects
Stimulation - In terms of its effects on the physical energy levels of the user, MiPLA is regarded as being able primarily stimulating in nature in the same vein as LSD. This is in distinction to other, more commonly used psychedelics such as psilocybin which are more consistent in producing sedation and relaxedness.
Spontaneous bodily sensations - The "body high" of MiPLA can be described as proportionally intense in comparison to its accompanying visual and cognitive effects. It behaves as a euphoric, fast-moving, sharp and location specific tingling sensation. For some, it is manifested spontaneously at different unpredictable points throughout the experience, but for most it maintains a steady presence that rises with the onset and hits its limit once the peak has been reached. In comparison to LSD, it is a little less sharp in the tingling sensations it produces as but is otherwise essentially indistinguishable.
Physical euphoria - It should be noted that this effect is not as reliably induceable as it is with substances like stimulants or entactogens, and can just as easily manifest as physical discomfort without any apparent reason.
Changes in felt bodily form - This effect is often accompanied by a sense of warmth or unity and usually occurs during and up to the peak of the experience or directly afterward. Users can feel as if they are physically part of or conjoined with other objects. This is usually reported as feeling comfortable and peaceful in its sensations.
Tactile enhancement - Feelings of enhanced tactile sensations are consistently present at moderate levels throughout most MiPLA trips. If level 8A geometry is reached, an intense sensation of suddenly becoming aware of and being able to feel every single nerve ending across a person's entire body all at once becomes consistently present.
Temperature regulation suppression - This component can occur with the use of any lysergamide or psychedelic, but reports suggest it may be pronounced in MiPLA. It is highly advised that users of this compound, especially at heavier doses, monitor their bodily temperature and use techniques like hot showers or cold packs to regulate their core and brain temperature throughout the experience, and to generally always maintain proximity to a climate-controlled environment.
Nausea - Mild nausea is occasionally reported when this substance is consumed in moderate to high dosages, usually during the peak, and either passes soon after the user has vomited or gradually fades by itself as the peak sets in.
Seizure - The possibility of seizures is extrapolated from the seizures that have been reported following the use of LSD. They are thought to mainly be a risk in those who are genetically predisposed to them, particularly while accompanied by physically taxing conditions such as dehydration, fatigue or undernourishment.
Drifting(melting, breathing, morphing and flowing) - In comparison to other psychedelics, this effect can be described as highly detailed yet cartoon-like in appearance. The distortions are slow and smooth in motion and fleeting in their appearance. This is nearly identical in appearance to the visual drifting which occurs under the influence of LSD.
The visual geometry evoked by MiPLA can be described as more similar in appearance to that of LSD, 2C-B or 4-HO-MET than psilocin, LSA or DMT. It can be comprehensively described through its variations as primarily intricate in complexity, algorithmic in form, unstructured in organization, brightly lit, colourful and cartoonish in scheme, organic in feel, flat in shading, soft in its edges, large in size, slow in speed, smooth in motion, either angular or round in its corners, non-immersive in-depth and consistent in intensity. At higher dosages, it consistently results in states of Level 8B visual geometry over Level 8A.
In comparison to LSD specifically, MiPLA's geometry tends to be more rounded in its corners, slightly softer in its edges, warmer in hue, and slightly less intricate in its form. Aside from this, it is otherwise identical in its appearance.
Hallucinatory states
MiPLA is capable of producing a full range of low and high level hallucinatory states in a fashion that is a less consistent and reproducible than that of many other commonly used psychedelics such as psilocin or DMT but considerably more likely to when compared to that of LSD. This can feel similar to the hallucinations which occur with 4-AcO-DMT but tends to occur almost exclusively at heavierdoses. Some of these effects include:
Internal hallucination (autonomous entities; settings, sceneries, and landscapes; perspective hallucinations and scenarios and plots) - This effect is very consistent in dark environments at appropriately high dosages. They can be comprehensively described through their variations as lucid in believability, interactive in style, new experiences in content, autonomous in controllability, geometry-based in style and occasionally of a personal, religious, spiritual, science-fiction, fantasy, surreal, nonsensical or transcendental nature in their overall theme.
In comparison to other psychedelics such as psilocin, LSA and ayahuasca, MiPLA is significantly more stimulating and fast-paced in terms of the specific style of thought stream which it produces and contains a large number of potential effects associated with both psychedelic tryptamines and phenethylamines. In comparison to LSD, it is often reported to be less anxiety-provoking and generally more emotionally comfortable and forgiving.
The most prominent of these cognitive effects generally include:
Cognitive euphoria - This component is, generally speaking less consistent and pronounced than it is with substances like psilocybin and MDMA. The mental euphoria experienced on MiPLA is usually simply due to an enhancement of the user’s current psychological and emotional state coupled with its more regularly occurring effect, physical euphoria.
The toxicity and long-term health effects of recreational MiPLA use has not been studied in any scientific context and the exact toxic dose is unknown. This is because MiPLA is a research chemical with very little history of human usage.
The body of anecdotal reports suggests that there are no negative health effects attributed to simply trying the substance by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.
As with other psychedelic substances, there are relatively few physical side effects that have been reported associated with acute MiPLA exposure. Although no formal studies have been conducted, it is likely that as with LSD itself, MiPLA is able to be considered non-addictive, with an extremely low toxicity relative to dose.[1] It is also likely that as with LSD, there are little to no negative physical, cognitive, psychiatric or other toxic consequences associated with acute MiPLA exposure.
However, as with LSD and psychedelics in general, it is possible that MiPLA can act as a potential trigger for those with underlying psychiatric conditions. Those with a personal or family history of mental illness are generally advised not to use this substance, particularly outside of a supervised medical setting.
Although no formal studies have been conducted, it is not unreasonable to assume that as with LSD itself, MiPLA is not habit-forming and that the desire to use it can actually decrease with use.
Tolerance to the effects of MiPLA are built almost immediately after ingestion. After that, it takes about 5-7 days for the tolerance to be reduced to half and 14 days to be back at baseline (in the absence of further consumption). MiPLA presents cross-tolerance with [[Cross-tolerance::all psychedelics]], meaning that after the use of MiPLA all psychedelics will have a reduced effect.
Owing to its activity at the 5-HT2A receptor, MiPLA presents cross-tolerance with [[Cross-tolerance::all psychedelics]], meaning that after the consumption of MiPLA all psychedelics will have a reduced effect.
Overdose
The LD50 of MiPLA is unknown. Adverse psychological reactions may be become more likely to occur at higher doses. Some of these include anxiety, delusions, panic attacks and more rarely seizures. Medical attention is usually only needed if suspected of severe psychotic episodes or “fake acid” (such as 25i-NBOMe or DOB). Administration of benzodiazepines or antipsychotics can help to relieve the negative cognitive effects of MiPLA.
Dangerous interactions
Warning:Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).
Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.
Tramadol - Tramadol lowers the seizure threshold[2] and psychedelics may act as triggers for seizures, particularly in those who are predisposed to them.[citation needed]
Stimulants - Stimulants affect many parts of the brain. Combined with psychedelics, stimulation can turn into uncontrollable anxiety, panic, thought loops and paranoia. This interaction may cause elevated risk of psychosis.[citation needed]
Lithium - Lithium is often used as treatment for bipolar disorder. It may possibly cause elevated risk of seizures and psychosis due to its glutaminergic and GABAergic effects.[citation needed]
Literature
Halberstadt, A. L., Klein, L. M., Chatha, M., Valenzuela, L. B., Stratford, A., Wallach, J., ... & Brandt, S. D. (2018). Pharmacological characterization of the LSD analog N-ethyl-N-cyclopropyl lysergamide (ECPLA). Psychopharmacology, 1-10. http://dx.doi.org/10.1007/s00213-018-5055-9
↑Talaie, H., Panahandeh, R., Fayaznouri, M. R., Asadi, Z., & Abdollahi, M. (2009). Dose-independent occurrence of seizure with tramadol. Journal of medical toxicology, 5(2), 63-67. doi:10.1007/BF03161089
